Effects of omalizumab in Aspergillus-associated airway disease
Open Access
- 11 March 2011
- Vol. 66 (6), 539-540
- https://doi.org/10.1136/thx.2010.153312
Abstract
The clinical spectrum of Aspergillus-associated airway diseases (AAAD) includes Aspergillus-induced asthma, allergic bronchopulmonary aspergillosis (ABPA) and bronchocentric granulomatosis. Corticosteroids are almost always used to suppress the immunological response to the fungal antigens.1 Although there are no evidence-based alternative treatment options besides steroids, the well-known adverse effects of these drugs have prompted clinicians to look beyond this standard practice and several cases of ABPA patients with very positive outcomes after omalizumab therapy have been recently published.2–6 We recruited 18 patients (13 women; mean age 49±17 years) with AAAD (2 of them had been previously diagnosed with cystic fibrosis) from 11 Spanish hospitals. All of them had been treated …Keywords
This publication has 7 references indexed in Scilit:
- Measured Immunoglobulin E in Allergic Bronchopulmonary Aspergillosis Treated With OmalizumabJournal of Asthma, 2010
- Effective Anti-immunoglobulin-E Antibody Treatment of a Patient With Allergic Bronchopulmonary AspergillosisArchivos de Bronconeumología, 2009
- Longitudinal assessment of lung function from infancy to childhood in patients with cystic fibrosisPediatric Pulmonology, 2009
- Allergic Bronchopulmonary AspergillosisSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2009
- Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti‐IgE antibody (omalizumab)Pediatric Pulmonology, 2008
- Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibodyThorax, 2007
- Clinical and Immunologic Criteria for the Diagnosis of Allergic Bronchopulmonary AspergillosisAnnals of Internal Medicine, 1977